Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
GEOVAX LABS INC (GOVX) Stock Price & Overview
NASDAQ:GOVX • US3736787058
Current stock price
1.155 USD
+0.06 (+5.96%)
At close:
1.1596 USD
+0 (+0.4%)
After Hours:
The current stock price of GOVX is 1.155 USD. Today GOVX is up by 5.96%. In the past month the price decreased by -13.16%. In the past year, price increased by 14.36%.
GOVX Key Statistics
52-Week Range0.1151 - 4.4
Current GOVX stock price positioned within its 52-week range.
1-Month Range0.9631 - 1.51
Current GOVX stock price positioned within its 1-month range.
- Market Cap
- 2.564M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -27.75
- Dividend Yield
- N/A
GOVX Stock Performance
Today
+5.96%
1 Week
+5.96%
1 Month
-13.16%
3 Months
-58.75%
Longer-term
6 Months +104.17%
1 Year +14.36%
2 Years -36.54%
3 Years -87.58%
5 Years -98.58%
10 Years N/A
GOVX Stock Chart
GOVX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GOVX. When comparing the yearly performance of all stocks, GOVX is a bad performer in the overall market: 87.11% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
GOVX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GOVX. GOVX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GOVX Earnings
Next Earnings DateJul 27, 2026
Last Earnings DateApr 29, 2026
PeriodQ4 / 2025
EPS Reported-$0.01
Revenue Reported
EPS Surprise 99.92%
Revenue Surprise %
GOVX Forecast & Estimates
10 analysts have analysed GOVX and the average price target is 272 USD. This implies a price increase of 23449.78% is expected in the next year compared to the current price of 1.155.
For the next year, analysts expect an EPS growth of -0.14% and a revenue growth -100% for GOVX
Analysts
Analysts80
Price Target272 (23449.78%)
EPS Next Y-0.14%
Revenue Next Year-100%
GOVX Financial Highlights
Over the last trailing twelve months GOVX reported a non-GAAP Earnings per Share(EPS) of -27.75. The EPS increased by 80.42% compared to the year before.
Income Statements
Revenue(TTM)2.49M
Net Income(TTM)-21.46M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -338.46% | ||
| ROE | -561.15% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%99.93%
Sales Q2Q%-100%
EPS 1Y (TTM)80.42%
Revenue 1Y (TTM)-37.06%
GOVX Ownership
Ownership
Inst Owners5.32%
Shares2.22M
Float2.22M
Ins Owners0.03%
Short Float %12.5%
Short Ratio2.51
GOVX Industry Overview
GOVX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
26%
Outperformed 26% of sub-industries
3 Month Rank
50%
Outperformed 50% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.1%
- New Lows
- 4.6%
- Average ROE
- 48.5%
- Average Profit Margin
- 20.5%
- Average Operating Margin
- 33.6%
- Average P/E
- 22.9
- Average Fwd P/E
- 18.2
- Average Debt/Equity
- 2.2
GOVX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 373.774B | ||
| AMGN | AMGEN INC | 13.88 | 186.868B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 162.401B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 108.708B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 41.295B | ||
| INSM | INSMED INC | N/A | 29.427B | ||
| NTRA | NATERA INC | N/A | 29.219B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.56B | ||
| BIIB | BIOGEN INC | 11.44 | 27.779B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.042B | ||
| INCY | INCYTE CORP | 10.61 | 18.96B | ||
| MRNA | MODERNA INC | N/A | 18.219B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GOVX
Company Profile
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
Company Info
IPO: 1994-04-04
GEOVAX LABS INC
1955 Lake Park Drive, Suite 300
Smyrna GEORGIA 30080 US
CEO: David A. Dodd
Employees: 17
Phone: 16783847220
GEOVAX LABS INC / GOVX FAQ
What does GEOVAX LABS INC do?
GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is headquartered in Smyrna, Georgia and currently employs 17 full-time employees. Its lead clinical program is GEO-CM04S1, a COVID-19 vaccine, which is in three phase II clinical trials, being evaluated as a primary vaccine for immunocompromised patients, such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient; a booster vaccine in patients with chronic lymphocytic leukemia (CLL); and a COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology, the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin, having completed a multicenter Phase I/II clinical trial for advanced head and neck cancers. The company is developing GEO-MVA, a vaccine targeting Mpox and smallpox. Its other product candidates include GEO-EM01-Z, GEO-EM01-S, GEO-MM01, GEO-ZM02 and others.
What is the current price of GOVX stock?
The current stock price of GOVX is 1.155 USD. The price increased by 5.96% in the last trading session.
What is the dividend status of GEOVAX LABS INC?
GOVX does not pay a dividend.
What is the ChartMill technical and fundamental rating of GOVX stock?
GOVX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting GOVX stock to perform?
10 analysts have analysed GOVX and the average price target is 272 USD. This implies a price increase of 23449.78% is expected in the next year compared to the current price of 1.155.
What is the expected growth for GOVX stock?
The Revenue of GEOVAX LABS INC (GOVX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of GEOVAX LABS INC (GOVX) stock?
The outstanding short interest for GEOVAX LABS INC (GOVX) is 12.5% of its float.